| 年份 | 产品分类 | 收入(万元) | 收入占比(%) | 成本占比(%) | 利润占比(%) | 毛利率(%) |
|---|---|---|---|---|---|---|
| 2025-12-31 | 研发技术成果转化 | 24730 | 36.4765 | 20.7787 | 60.5169 | 65.5382 |
| 2025-12-31 | 临床服务 | 13617 | 20.085 | 23.7882 | 14.4138 | 28.349 |
| 2025-12-31 | 临床前药学研究 | 12189 | 17.9789 | 17.8285 | 18.2092 | 40.0092 |
| 2025-12-31 | CDMO | 4411 | 6.5064 | 5.7142 | 7.7196 | 46.8692 |
| 2025-06-30 | 研发技术成果转化 | 10698 | 32.1908 | 16.4738 | 47.4528 | 74.7883 |
| 2025-06-30 | 临床服务 | 8143 | 24.5026 | 25.562 | 23.4739 | 48.6046 |
| 2025-06-30 | 临床前药学研究 | 7830 | 23.562 | 21.4037 | 25.6579 | 55.2474 |
| 2024-12-31 | 研发技术成果转化 | 28777 | 35.885 | 19.9569 | 50.5983 | 73.2958 |
| 2024-12-31 | 临床服务 | 21308 | 26.5721 | 34.3977 | 19.3433 | 37.8408 |
| 2024-12-31 | 临床前药学研究 | 19354 | 24.1345 | 22.254 | 25.8716 | 55.7238 |
| 2024-06-30 | 研发技术成果转化 | 24880 | 47.3854 | 22.1203 | 58.8683 | 85.4131 |
| 2024-06-30 | 临床服务 | 9258 | 17.6333 | 35.3383 | 9.5865 | 37.3777 |
| 2024-06-30 | 临床前药学研究 | 15432 | 29.3915 | 29.5105 | 29.3374 | 68.6258 |
| 2023-12-31 | 研发技术成果转化 | 39241 | 38.569 | 23.9185 | 46.2762 | 78.6221 |
| 2023-12-31 | 临床服务 | 19287 | 18.957 | 30.7856 | 12.7344 | 44.0182 |
| 2023-12-31 | 临床前药学研究 | 33811 | 33.2312 | 33.974 | 32.8404 | 64.7572 |
| 2023-06-30 | 研发技术成果转化 | 19012 | 44.8554 | 23.1033 | 55.7841 | 82.7758 |
| 2023-06-30 | 临床服务 | 7002 | 16.52 | 30.0238 | 9.7354 | 39.2238 |
| 2023-06-30 | 临床前药学研究 | 12466 | 29.4106 | 36.7563 | 25.72 | 58.2068 |
| 2022-12-31 | 研发技术成果转化 | 22087 | 36.3642 | 24.5043 | 42.1076 | 78.014 |
| 2022-12-31 | 权益分成 | 5779 | 9.5152 | 14.1232 | ||
| 2022-12-31 | 临床服务 | 7994 | 13.1621 | 22.0458 | 8.86 | 45.3518 |
| 2022-12-31 | 临床前药学研究 | 21840 | 35.9564 | 43.5328 | 32.2873 | 60.4981 |
| 2022-06-30 | 研发技术成果转化 | 6916 | 28.1557 | 19.7473 | 32.5677 | 75.8634 |
| 2022-06-30 | 权益分成 | 3094 | 12.5964 | 0.2482 | 19.0756 | 99.322 |
| 2022-06-30 | 临床服务 | 4342 | 17.6769 | 27.4409 | 12.5536 | 46.5773 |
| 2022-06-30 | 临床前药学研究 | 9034 | 36.775 | 44.2044 | 32.8768 | 58.6338 |
| 2021-12-31 | 研发技术成果转化 | 10584 | 28.2759 | 24.2205 | 30.2495 | 71.9597 |
| 2021-12-31 | 权益分成 | 3217 | 8.5948 | 12.7776 | ||
| 2021-12-31 | 临床服务 | 5411 | 14.4573 | 22.5422 | 10.5227 | 48.9585 |
| 2021-12-31 | 临床前药学研究 | 15943 | 42.5949 | 43.3593 | 42.2229 | 66.6773 |
| 2021-06-30 | 自主研发技术成果转化 | 3732 | 26.42 | 16.0371 | 31.6149 | 79.7575 |
| 2021-06-30 | 受托药品研发服务 | 8556 | 60.5745 | 78.6064 | 51.5525 | 56.7247 |
| 2021-06-30 | 其他 | 1837 | 13.0056 | 5.3566 | 16.8326 | 86.265 |
| 2021-06-30 | 其中:临床服务 | 2822 | 19.9828 | 29.8182 | 15.0619 | 50.2382 |
| 2021-06-30 | 其中:临床前药学研究 | 5734 | 40.5916 | 48.7882 | 36.4906 | 59.918 |
| 2020-12-31 | 研发技术成果转化 | 5481 | 26.4474 | 12.4513 | 33.7178 | 83.905 |
| 2020-12-31 | 受托药品研发服务 | 14288 | 68.9452 | 82.5227 | 61.8922 | 59.0805 |
| 2020-12-31 | 其中:临床服务 | 6295 | 30.378 | 32.4091 | 29.323 | 63.5273 |
| 2020-12-31 | 临床前药学研究 | 7992 | 38.5671 | 50.1136 | 32.5692 | 55.5779 |
| 2020-06-30 | 自主研发技术成果转化 | 2042 | 25.179 | 10.6474 | 33.7637 | 84.2959 |
| 2020-06-30 | 受托药品研发服务 | 5614 | 69.2038 | 84.456 | 60.1934 | 54.6781 |
| 2020-06-30 | 其他 | 455 | 5.6172 | 4.8966 | 6.0429 | 67.6271 |
| 2020-06-30 | 其中:临床服务 | 2194 | 27.0477 | 29.5212 | 25.5865 | 59.4668 |
| 2020-06-30 | 其中:临床前药学研究 | 3420 | 42.1561 | 54.9348 | 34.6069 | 51.6056 |
| 2019-12-31 | 研发技术成果转化 | 2724 | 17.4181 | 8.1645 | 23.0416 | 82.2819 |
| 2019-12-31 | 受托药品研发服务 | 12215 | 78.0965 | 87.1841 | 72.574 | 57.8019 |
| 2019-12-31 | 其中:临床服务 | 4050 | 25.8949 | 38.7169 | 18.1029 | 43.4838 |
| 2019-12-31 | 临床前药学研究 | 8165 | 52.2016 | 48.4672 | 54.471 | 64.9045 |
| 2018-12-31 | 研发技术成果转化 | 1019 | 12.4092 | 4.7609 | 18.9133 | 82.368 |
| 2018-12-31 | 受托药品研发服务 | 6879 | 83.7756 | 92.7085 | 76.179 | 49.1419 |
| 2018-12-31 | 其中:临床服务 | 3165 | 38.5408 | 45.967 | 32.2255 | 45.1869 |
| 2018-12-31 | 临床前药学研究 | 3714 | 45.2348 | 46.7415 | 43.9536 | 52.5116 |
| 2017-12-31 | 受托药品研发服务 | 2361 | 92.2889 | 96.3843 | 86.0775 | 37.0605 |
| 2017-12-31 | 其他 | 176 | 6.9015 | 2.2788 | 13.9128 | 80.1014 |
| 2017-12-31 | 其中:临床服务 | 508 | 19.8735 | 26.7502 | 9.4436 | 18.8814 |
| 2017-12-31 | 临床前药学研究 | 1852 | 72.4154 | 69.634 | 76.634 | 42.0495 |
| 2017-06-30 | 医药研发项目 | 1192 | 97.9953 | 100.0 | 96.2573 | 52.6142 |
| 2016-12-31 | 药研发项目 | 2287 | 96.0724 | 97.9536 | 95.025 | 63.5359 |
| 2016-06-30 | 医药研发项目 | 583 | 96.2708 | 100.0 | 92.7591 | 49.6237 |
| 2015-12-31 | 药研发项目 | 1606 | 99.078 | 100.0 | 98.6702 | 69.0487 |
| 2015-09-30 | 医药研发项目 | 1046 | 98.9328 | 100.0 | 98.3741 | 65.2713 |
| 2014-12-31 | 药研发项目 | 586 | 98.3944 | 100.0 | 93.0988 | 22.0136 |
| 2013-12-31 | 药研发项目 | 285 | 95.272 | 100.0 | 85.3446 | 28.8993 |
| 年份 | 产品分类 | 收入(万元) | 收入占比(%) | 成本占比(%) | 利润占比(%) | 毛利率(%) |
|---|---|---|---|---|---|---|
| 2025-12-31 | 商业化生产 | 8928 | 13.1685 | 28.6479 | -10.5373 | -31.6099 |
| 2025-12-31 | CRO | 54459 | 80.3251 | 65.6379 | 102.818 | 50.5647 |
| 2025-12-31 | CDMO | 4411 | 6.5064 | 5.7142 | 7.7196 | 46.8692 |
| 2025-06-30 | 商业化生产 | 3415 | 10.2752 | 27.3438 | -6.299 | -31.1019 |
| 2025-06-30 | CRO | 28656 | 86.2219 | 68.3436 | 103.583 | 60.9499 |
| 2025-06-30 | CDMO | 1164 | 3.5028 | 4.3127 | 2.7165 | 39.3449 |
| 2024-12-31 | 商业化生产 | 3669 | 4.5758 | 13.4276 | -3.6009 | -40.9078 |
| 2024-12-31 | CRO | 72350 | 90.2214 | 80.5732 | 99.1337 | 57.1173 |
| 2024-12-31 | CDMO | 4172 | 5.2028 | 5.9992 | 4.4672 | 44.6325 |
| 2024-06-30 | 商业化生产 | 251 | 0.4796 | 3.5674 | -0.9238 | -132.418 |
| 2024-06-30 | CRO业务 | 51742 | 98.5452 | 95.0726 | 100.123 | 69.8534 |
| 2024-06-30 | CDMO | 512 | 0.9752 | 1.3599 | 0.8004 | 56.4254 |
| 2023-12-31 | CRO | 96495 | 94.8407 | 91.3398 | 96.6824 | 66.8002 |
| 2023-12-31 | CDMO | 5249 | 5.1593 | 8.6602 | 3.3176 | 42.1363 |
| 2023-06-30 | CRO业务 | 40658 | 95.9242 | 93.1238 | 97.3312 | 67.5353 |
| 2023-06-30 | CDMO业务 | 1727 | 4.0758 | 6.8762 | 2.6688 | 43.5827 |
| 2022-12-31 | CRO业务 | 58660 | 96.5753 | 92.8689 | 98.3701 | 68.6251 |
| 2022-12-31 | CDMO | 2080 | 3.4247 | 7.1311 | 1.6299 | 32.0632 |
| 2022-06-30 | CRO业务 | 23832 | 97.011 | 94.3194 | 98.4233 | 66.5409 |
| 2022-06-30 | CDMO业务 | 734 | 2.989 | 5.6806 | 1.5767 | 34.597 |
| 2021-12-31 | CRO业务 | 36491 | 97.4884 | 94.8449 | 98.7748 | 68.1524 |
| 2021-12-31 | CDMO | 940 | 2.5116 |
| 年份 | 产品分类 | 收入(万元) | 收入占比(%) | 成本占比(%) | 利润占比(%) | 毛利率(%) |
|---|---|---|---|---|---|---|
| 2025-12-31 | 国外 | 44 | 0.0658 | 0.1667 | ||
| 2025-12-31 | 国内 | 67754 | 99.9342 | 100.0 | 99.8333 | 39.4633 |
| 2025-06-30 | 境外 | 11 | 0.036 | 0.1007 | -0.0268 | -37.7696 |
| 2025-06-30 | 境内 | 33223 | 99.964 | 99.8993 | 100.027 | 50.7665 |
| 2024-12-31 | 国外 | 32 | 0.0409 | 0.0787 | ||
| 2024-12-31 | 国内 | 80159 | 99.9591 | 100.0 | 99.9213 | 51.9627 |
| 2024-06-30 | 境内 | 52503 | 99.994 | 100.0 | 99.9913 | 68.7505 |
| 2023-12-31 | 国内 | 101744 | 100.0 | 100.0 | 100.0 | 65.5278 |
| 2022-12-31 | 国内 | 60741 | 100.0 | 100.0 | 100.0 | 67.373 |
| 2021-12-31 | 国内 | 37431 | 100.0 | 94.8449 | 102.509 | 68.9523 |
| 2021-06-30 | 西南 | 403 | 2.8578 | |||
| 2021-06-30 | 西北 | 124 | 0.8835 | |||
| 2021-06-30 | 华南 | 1688 | 11.9527 | |||
| 2021-06-30 | 华北 | 850 | 6.0181 | |||
| 2021-06-30 | 华中 | 182 | 1.2904 | |||
| 2021-06-30 | 华东 | 10831 | 76.6773 | |||
| 2021-06-30 | 其他 | 27 | 0.1939 | |||
| 2021-06-30 | 东北 | 17 | 0.1262 | |||
| 2020-12-31 | 西南 | 968 | 4.6741 | |||
| 2020-12-31 | 西北 | 139 | 0.6754 | |||
| 2020-12-31 | 华南 | 3547 | 17.1181 | |||
| 2020-12-31 | 华北 | 1499 | 7.2369 | |||
| 2020-12-31 | 华中 | 44 | 0.2136 | |||
| 2020-12-31 | 华东 | 14316 | 69.0805 | |||
| 2020-12-31 | 东北 | 207 | 1.0015 | |||
| 2020-06-30 | 西南 | 207 | 2.5559 | |||
| 2020-06-30 | 西北 | 32 | 0.3945 | |||
| 2020-06-30 | 华南 | 1600 | 19.7262 | |||
| 2020-06-30 | 华北 | 428 | 5.2801 | |||
| 2020-06-30 | 华中 | 7 | 0.0875 | |||
| 2020-06-30 | 华东 | 5650 | 69.6483 | |||
| 2020-06-30 | 东北 | 187 | 2.3075 | |||
| 2019-12-31 | 西南 | 749 | 4.7903 | |||
| 2019-12-31 | 西北 | 166 | 1.0675 | |||
| 2019-12-31 | 华南 | 1808 | 11.5589 | |||
| 2019-12-31 | 华北 | 692 | 4.4289 | |||
| 2019-12-31 | 华中 | 114 | 0.7301 | |||
| 2019-12-31 | 华东 | 12006 | 76.7585 | |||
| 2019-12-31 | 东北 | 104 | 0.6656 | |||
| 2018-12-31 | 西南 | 21 | 0.2612 | |||
| 2018-12-31 | 西北 | 13 | 0.1624 | |||
| 2018-12-31 | 华南 | 150 | 1.829 | |||
| 2018-12-31 | 华北 | 60 | 0.7407 | |||
| 2018-12-31 | 华中 | 87 | 1.0701 | |||
| 2018-12-31 | 华东 | 7582 | 92.3313 | |||
| 2018-12-31 | 东北 | 296 | 3.6051 | |||
| 2017-12-31 | 西南 | 40 | 1.5845 | |||
| 2017-12-31 | 华南 | 79 | 3.1025 | |||
| 2017-12-31 | 华北 | 73 | 2.868 | |||
| 2017-12-31 | 华中 | 45 | 1.7791 | |||
| 2017-12-31 | 华东 | 2211 | 86.4281 | |||
| 2017-12-31 | 东北 | 108 | 4.2379 | |||
| 2017-06-30 | 国内销售 | 1216 | 100.0 | 100.0 | 100.0 | 53.5641 |
| 2016-12-31 | 国内 | 2380 | 100.0 | 100.0 | 100.0 | 64.2362 |
| 2016-06-30 | 国内销售 | 606 | 100.0 | 100.0 | 100.0 | 51.5024 |
| 2015-12-31 | 国内 | 1621 | 100.0 | 100.0 | 100.0 | 69.3341 |
| 2015-09-30 | 国内销售 | 1058 | 100.0 | 100.0 | 100.0 | 65.6419 |
| 2014-12-31 | 国内 | 595 | 100.0 | 100.0 | 100.0 | 23.2658 |
| 2013-12-31 | 国内 | 299 | 100.0 | 100.0 | 100.0 | 32.2609 |